Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 15 trials

Late-Stage Pipeline

7%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

9 recruiting

Enrollment Performance

Analytics

Phase 1
10(71.4%)
N/A
1(7.1%)
Phase 3
1(7.1%)
Early Phase 1
1(7.1%)
Phase 2
1(7.1%)
14Total
Phase 1(10)
N/A(1)
Phase 3(1)
Early Phase 1(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials
NCT07109986Phase 1Recruiting

UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis

Role: lead

NCT07309900Phase 1Recruiting

IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies

Role: collaborator

NCT06743503Phase 1Recruiting

UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies

Role: lead

NCT06464991Phase 3Recruiting

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

Role: lead

NCT07055724Phase 2Not Yet Recruiting

Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis

Role: lead

NCT07028970Recruiting

Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection

Role: lead

NCT05219721Phase 1Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Role: collaborator

NCT05759793Phase 1Recruiting

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Role: lead

NCT06902844Not ApplicableRecruiting

Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Role: collaborator

NCT04561557Early Phase 1Recruiting

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Role: collaborator

NCT05698303Phase 1Unknown

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Role: lead

NCT05201118Phase 1Unknown

A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

Role: collaborator

NCT05181501Phase 1Not Yet Recruiting

A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)

Role: lead

NCT05066646Phase 1Unknown

A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)

Role: lead

NCT05091541Phase 1Not Yet Recruiting

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Role: lead

All 15 trials loaded